- This event has passed.
Glenn Seymour and Jenny Robeson, “HIFU: A Newly Approved Treatment for Prostate Cancer” (November 15)
November 15, 2017 @ 12:30 pm - 1:30 pm
Glenn Seymour, Senior Consultant, and Jenny Robeson, Chief Sales Officer
HIFU Prostate Services
HIFU: A Newly Approved Treatment for Prostate Cancer
HIFU Prostate Services (HPS) was founded in 2015 to provide men access to a less invasive treatment option for prostate cancer that has the ability to eliminate cancer and preserve patient quality of life. Their mission is to deliver the highest quality of care, support, and technology to the patient and to the urology community for the treatment of localized prostate cancer using Sonablate HIFU. HPS has a seasoned management team with over 60 years of HIFU experience from SonaCare Medical. HPS is the first, largest, and most experienced HIFU team in the U.S. and has been involved in over 3,000 HIFU procedures.
Glenn Seymour serves HPS as a HIFU consultant and has 10 years of experience involving radiation therapy, specifically, prostate and breast cancer treatment having served as marketing and national sales manager for Sicel Technology.
Jenny Robeson joined HPS in 2016 as Chief Sales Officer and brings over 18 years of medical device, pharmaceutical and biotech sales experience to the company, including six years with SonaCare Medical, the manufacturer of the Sonablate HIFU system. Most of her career has been focused on urology products and growing sales within the urology community and especially early adopters of new prostate cancer therapies and pharmaceuticals. Robeson graduated from The University of North Carolina at Chapel Hill, School of public Health, with a B.S. in Human Nutrition and Biology. She also received a Master’s in Human Nutrition from Winthrop University.